{"preliminary_commentary":{"by_channel":{"x_thread":19,"podcast":2,"youtube":1},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT05148546\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"commentary_summary":{"generated_at":"2026-11-01T14:28:24.815Z","note":"Automated from the 21 newest of 22 indexed sources (Apr 2022 – Jul 2026). Each question is raised in at least two. Not an Erudio report: no source links. Not medical advice.","passages_read":21,"text":"- How to identify patients most likely to benefit from perioperative immunotherapy\n- How neoadjuvant immunotherapy should fit into perioperative treatment\n- Which endpoints best capture benefit from neoadjuvant immunotherapy"},"drugs_tested":[["nivolumab"],["nivolumab","ipilimumab"],["nivolumab","relatlimab"]],"indication":"resectable clear cell renal cell carcinoma","name":"NESCIO","nct_id":"NCT05148546","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=nescio-nct05148546. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1950,"size":"deep","size_rule":"Deep: 301+ verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"NESCIO","arms":[{"description":"Neoadjuvant 2 cycles of nivolumab 360mg every 3 weeks","label":"A: Neoadjuvant nivolumab","type":"EXPERIMENTAL"},{"description":"Neoadjuvant 2 cycles of nivolumab 3 mg/kg + ipilimumab 1 mg/kg every 3 weeks","label":"B: Neoadjuvant nivolumab + ipilimumab","type":"EXPERIMENTAL"},{"description":"Neoadjuvant 2 cycles of nivolumab 360mg + relatlimab 360mg every 3 weeks","label":"C: Neoadjuvant nivolumab + relatlimab","type":"EXPERIMENTAL"}],"collaborators":["Bristol-Myers Squibb"],"completion_date":{"date":"2029-04","type":"ESTIMATED"},"conditions":["Renal Cell Carcinoma"],"enrollment":{"count":69,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"Neoadjuvant nivolumab","otherNames":["Opdivo"],"type":"DRUG"},{"name":"Neoadjuvant ipilimumab","otherNames":["Yervoy"],"type":"DRUG"},{"name":"Neoadjuvant relatlimab","otherNames":[],"type":"DRUG"}],"last_update":"2025-09-30","lead_sponsor":"The Netherlands Cancer Institute","official_title":"Prospective, Randomized, Neoadjuvant Phase II Study With Combination Immuno-oncology in Primary Clear Cell Renal Cancer at Risk for Recurrence or Distant Metastases (NESCIO-trial)","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE2"],"primary_completion_date":{"date":"2025-04-22","type":"ACTUAL"},"primary_outcomes":[{"measure":"Pathologic response rate","timeFrame":"At 6 weeks"}],"references":[],"start_date":{"date":"2022-04-28","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Neoadjuvant Study With Combination Immuno-oncology for Primary Clear Cell Renal Cell Cancer","url":"https://clinicaltrials.gov/study/NCT05148546"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.1","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/nescio-nct05148546"}